polymerase

Nucleoside and nucleotide analogues are synthetic, chemically modified compounds that have been developed to mimic their physiological counterparts in order to exploit cellular metabolism and subsequently be incorporated into DNA and RNA to inhibit cellular division and viral replication. In addition to their incorporation into nucleic acids, nucleoside and nucleotide analogues can interact with and inhibit essential enzymes such as human and viral polymerases (that is, DNA-dependent DNA polymerases, RNA-dependent DNA polymerases or RNA-dependent RNA polymerases), kinases, ribonucleotide reductase, DNA methyltransferases, purine and pyrimidine nucleoside phosphorylase and thymidylate synthase. These actions of nucleoside and nucleotide analogues have potential therapeutic benefits — for example, in the inhibition of cancer cell growth, the inhibition of viral replication as well as other indications.

MCE offers a unique collection of 544 nucleotide compounds including nucleotide, nucleoside and their structural analogues. MCE Nucleotide Compound Library is a useful tool to discover anti-cancer and antiviral drugs for high throughput screening (HTS) and high content screening (HCS).

Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.

MCE offers a unique collection of 295 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Transcription is the essential first step in the conversion of the genetic information in the DNA into protein and the major point at which gene expression is controlled. Transcription of protein-coding genes is accomplished by the multi-subunit enzyme RNA polymerase II and an ensemble of ancillary proteins, called transcription factors (TFs). Transcription factors play an important role in the long-term regulation of cell growth, differentiation and responses to environmental cues. Deregulated transcription factors contribute to the pathogenesis of a plethora of human diseases, ranging from diabetes, inflammatory disorders and cardiovascular disease to many cancers, and thus these proteins hold great therapeutic potential.

MCE offers a unique collection of 1,389 compounds with validated transcription factor targets modulating properties. MCE transcription factor-targeted compound library is an effective tool for researching transcription factors as drug targets as well as modulation of TFs for different therapeutic applications.

Phi29 DNA Polymerase is a mesophilic DNA polymerase cloned from Bacillus subtilis phage Phi29.

Phi29 DNA polymerase is a protein-engineered Phi29 DNA polymerase expressed in E. coli and then purified and isolated multiple times. Compared with wild-type Phi29 DNA polymerase, it has higher amplification efficiency and sensitivity, and can greatly shorten the reaction time.

MCE 2-Color Tracking SYBR qPCR Master Mix (Universal) is a 2× concentration premixed reagent utilizing a special performance-enhanced Taq DNA polymerase protected via a hot-start activation technique, and optimized qPCR buffer system to perform SYBR Green I based quantitative PCR (qPCR).

This product is a DNA polymerase obtained by expressing DNA Polymerase I (E. coli) in E. coli and purifying and isolating it multiple times.

Bst DNA Polymerase is derived from Bacillus stearothermophilus and has 5'→3' DNA polymerase activity and double-stranded specific 5'→3' exonuclease activity.

T4 DNA polymerase has 5´→3´ DNA polymerase activity and can catalyze the synthesis of DNA along the 5´→3´ direction with the presence of templates and primers.

Bst DNA Polymerase large fragment is a part of Bacillus stearothermophilus DNA polymerase, which is derived from E. coli strain. It is expressed in E. coli and purified and isolated multiple times.

Terminal Deoxynucleotidyl Transferase (TdT) is a template-independent DNA polymerase that catalyzes the binding of deoxynucleotides to the 3' hydroxyl end of oligonucleotides, single-stranded DNA, or double-stranded DNA.